Phenotypes associated with this allele

• Allele Symbol: Tet2^tm1Ics
• Allele Name: targeted mutation 1, Mouse Clinical Institute
• Allele ID: MGI:5141225
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Tet2^tm1Ics/Tet2^tm1Ics Tg(Mx1-cre)1Cgn/0	involves: C57BL/6 * CBA	MGI:5141273

Genotype
MGI:5141273

cn1

• Allelic Composition: Tet2^tm1Ics/Tet2^tm1Ics; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

mortality/aging ( J:174052 )

N • unlike Tet2^{Gt(AN0709)Wtsi} homozygous, pIpC-treated mice do not develop a lethal disorder

hematopoietic system

abnormal common myeloid progenitor cell morphology ( J:174052 )

• pIpC-treated mice exhibit increased common myeloid progenitors (CMP) and megakaryocyte-erythrocyte progenitors (MEP) compared with control mice

• however, pIpC-treated mice exhibit normal numbers of granulocyte-macrophage progenitor cells

decreased pro-B cell number ( J:174052 )

• in the bone marrow of pIpC-treated mice

extramedullary hematopoiesis ( J:174052 )

• in pIpC-treated mice

abnormal proerythroblast morphology ( J:174052 )

• pIpC-treated mice exhibit increased CD71+Ter119- proerythroblasts and a decreases CD71^lowTer119+ late erythroblasts in the bone marrow compared with control mice

increased erythroblast number ( J:174052 )

• pIpC-treated mice exhibit increased numbers of CD71+Ter119+ erythroid cells in the spleen compared with control mice

decreased erythrocyte cell number ( J:174052 )

• at 4 months in pIpC-treated mice

thrombocytopenia ( J:174052 )

• at 4 months in pIpC-treated mice

decreased pre-B cell number ( J:174052 )

• in the bone marrow of pIpC-treated mice

increased leukocyte cell number ( J:174052 )

• modest at 4 months in pIpC-treated mice

increased double-negative T cell number ( J:174052 )

• in the thymus of pIpC-treated mice

increased DN1 thymic pro-T cell number ( J:174052 )

• in the thymus of pIpC-treated mice

increased B cell number ( J:174052 )

• in the spleen of pIpC-treated mice

increased monocyte cell number ( J:174052 )

• pIpC-treated mice exhibit increased myelomonocytic CD11b+Gr1- cells in the peripheral blood and spleen compared with control mice

increased hematopoietic stem cell number ( J:174052 )

• pIpC-treated mice exhibit a slight increase in the absolute number of CD150+CD48- LSK cells compared with control mice

abnormal spleen morphology ( J:174052 )

• at 4 months, spleens in pIpC-treated mice exhibit infiltration of the lymphoid follicles with admixed maturing myeloid, immature erythroid, and maturing megakaryocytic elements unlike control mice

enlarged spleen ( J:174052 )

• at 4 months in some pIpC-treated mice

increased spleen red pulp amount ( J:174052 )

• at 4 months in pIpC-treated mice

liver/biliary system

abnormal liver sinusoid morphology ( J:174052 )

• at 4 months, pIpC-treated mice exhibit liver sinusoids with a lymphoid and trilineage myeloid elements and some focused perivascular infiltrations unlike control mice

enlarged liver ( J:174052 )

• at 4 months in some pIpC-treated mice

cardiovascular system

abnormal liver sinusoid morphology ( J:174052 )

• at 4 months, pIpC-treated mice exhibit liver sinusoids with a lymphoid and trilineage myeloid elements and some focused perivascular infiltrations unlike control mice

immune system

decreased pro-B cell number ( J:174052 )

• in the bone marrow of pIpC-treated mice

decreased pre-B cell number ( J:174052 )

• in the bone marrow of pIpC-treated mice

increased leukocyte cell number ( J:174052 )

• modest at 4 months in pIpC-treated mice

increased double-negative T cell number ( J:174052 )

• in the thymus of pIpC-treated mice

increased DN1 thymic pro-T cell number ( J:174052 )

• in the thymus of pIpC-treated mice

increased B cell number ( J:174052 )

• in the spleen of pIpC-treated mice

increased monocyte cell number ( J:174052 )

• pIpC-treated mice exhibit increased myelomonocytic CD11b+Gr1- cells in the peripheral blood and spleen compared with control mice

abnormal spleen morphology ( J:174052 )

• at 4 months, spleens in pIpC-treated mice exhibit infiltration of the lymphoid follicles with admixed maturing myeloid, immature erythroid, and maturing megakaryocytic elements unlike control mice

enlarged spleen ( J:174052 )

• at 4 months in some pIpC-treated mice

increased spleen red pulp amount ( J:174052 )

• at 4 months in pIpC-treated mice

endocrine/exocrine glands

increased DN1 thymic pro-T cell number ( J:174052 )

• in the thymus of pIpC-treated mice

growth/size/body

enlarged liver ( J:174052 )

• at 4 months in some pIpC-treated mice

enlarged spleen ( J:174052 )

• at 4 months in some pIpC-treated mice